quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:35:00·315d
PRRelease
Actinium Pharmaceuticals Inc. (Delaware) logo
Bio-Path Holdings Inc. logo
Envoy Medical Inc. logo
+5

Life Sciences Investor Forum: Now Available for Online Viewing

ATNM· Actinium Pharmaceuticals Inc. (Delaware)BPTH· Bio-Path Holdings Inc.COCH· Envoy Medical Inc.IMNN· Imunon Inc.MTVA· MetaVia Inc.SBC· SBC Medical Group Holdings Incorporated
Health Care
Original source

Companies

  • ATNM
    Actinium Pharmaceuticals Inc. (Delaware)
    Health Care
  • BPTH
    Bio-Path Holdings Inc.
    Health Care
  • COCH
    Envoy Medical Inc.
    Health Care
  • IMNN
    Imunon Inc.
    Health Care
  • MTVA
    MetaVia Inc.
    Health Care
  • SBC
    SBC Medical Group Holdings Incorporated
    Health Care
  • STSS
    Sharps Technology Inc.
    Health Care
  • TIVC
    Tivic Health Systems Inc.
    Health Care

Recent analyst ratings

  • Mar 31COCHUpdateH.C. Wainwright$2.50
  • Mar 6SBCUpdateBTIG Research$8.00
  • Sep 4MTVAUpdateH.C. Wainwright$12.00
  • Dec 30MTVAUpdateH.C. Wainwright$12.00
  • Aug 7ATNMUpdateB. Riley Securities$2.00
  • Jun 24COCHUpdateAscendiant Capital Markets$8.50

Related

  • INSIDER13h
    Chairman and CEO Aikawa Yoshiyuki sold $9,369,750 worth of shares (3,100,000 units at $3.02), decreasing direct ownership by 4% to 79,304,460 units (SEC Form 4)
  • SEC16h
    Tivic Health Systems Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
  • PR16h
    Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
  • SEC1d
    SBC Medical Group Holdings Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  • NEWS1d
    Emerging Growth Research Releases Flash Report on SBC Medical Group; Reiterates Buy-Extended Rating and $9.00 Price Target
  • PR2d
    Envoy Medical Reaches Critical Milestone in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant
  • PR2d
    Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
  • PR2d
    Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022